Table 1.
Patient characteristics (n=30)
| Characteristics | Number (%) |
|---|---|
| Sex | |
| Male | 20 (66.7) |
| Female | 10 (33.3) |
| Age | 51.2±13.9 (years) |
| Range | 25–80 |
| Recurrence | 30 (100) |
| DFI | 11.0±3.4 (months) |
| Histology | |
| WHO I | 0 (0) |
| WHO II | 23 (77.7) |
| WHO III | 7 (23.3) |
| Tumor stage | |
| I | 5 (16.7) |
| II | 8 (26.7) |
| III | 8 (26.7) |
| IV | 9 (30.0) |
| Previous radiotherapy | 30 (100) |
| Previous chemotherapy | 20 (66.7) |
Notes: WHO type I, keratinizing; type II, differentiated nonkeratinizing; type III, undifferentiated nonkeratinizing. Tumor stage according to TNM staging: stage I, T1 (confined to nasopharynx, or extension to oropharynx/nasal cavity without posterolateral spread), NO (no regional metastasis), M0 (no metastasis); stage II, T2 (extension into posterolateral pharyngeal soft tissues), N0, M0, or T2, N1 (unilateral metastasis to cervical nodes, <6 cm size, not level IV/Vb, and/or unilateral or bilateral involvement of retropharyngeal nodes, <6 cm size), M0; stage III, T3 (invasion of bony structures, skull base, and/or sinuses), N0 to N2 (bilateral metastasis to cervical nodes, <6 cm size, not level IV/Vb), M0, or T2, N2, M0; and stage IV, any T (T1, T2, T3, or T4: intracranial extension, cranial nerve involvement, spread to hypopharynx/orbit/infratemporal fossa), any N (N1, N2, or N3: involvement of nodes in levels IV/Vb, supraclavicular fossa), M0.27
Abbreviations: DFI, disease-free interval; M, metastasis; N, node; T, tumor; WHO, World Health Organization.